Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018.
Lisa has been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams.
Head of Corporate Strategy and Development
Bhavna is Head of Corporate Strategy and Development at C4X Discovery and a member of the Executive Team. She has over 13 years’ experience across investment banking, strategic consultancy, and life sciences commercialisation, having previously held roles at Lehman Brothers, Nomura International, PricewaterhouseCoopers and Cancer Research UK. At C4XD she focuses on applying her extensive experience in deal structuring and execution, strategic planning, portfolio positioning and investment strategy to drive the company towards achieving its objectives.
Director of Business Development and Membership Services
Jane joined the BIA in March 2016 as Director of Business Development and Membership Services, with overall responsibility for the recruitment and retention of members, development and delivery of membership services and BIA events.
Bird & Bird
Sally has wealth of experience working with businesses at the cutting edge of research and technology and whose intellectual property is of prime importance.
Sally is one of our leading intellectual property (IP) partners. She provides a full range of intellectual property commercial advice and support to her clients, including licensing, partnering and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and ‘freedom to operate’ matters, and manages significant due diligence matters. As a transactional intellectual property lawyer, she provides advice in relation to the protection and exploitation of a full range of IP rights, both in stand-alone transactions and as part of an acquisition, divestment or investment activity.